Integra LifeSciences Guides Q1 Revenue 2.8% Below Estimates, Margins Plunge
Integra LifeSciences guided first-quarter revenue of $382.5 million, 2.8% below analyst forecasts, after posting fourth-quarter revenue of $434.9 million and adjusted EPS of $0.83. The company’s operating margin plunged to 5.3% from 14.5% year-over-year, and free cash flow swung to negative $5.4 million.
1. Fourth-Quarter Results Exceed Estimates
Integra LifeSciences reported Q4 revenue of $434.9 million and adjusted EPS of $0.83, both topping consensus estimates. Despite the beats, revenue fell 1.7% year-over-year, signaling underlying sales pressure.
2. Weak First-Quarter Outlook
The company guided Q1 revenue of $382.5 million, representing a 2.8% shortfall to analyst estimates. This conservative outlook drove a 3.5% intraday share decline.
3. Profitability and Cash Flow Challenges
Operating margin collapsed to 5.3% from 14.5% a year ago, reflecting cost and pricing headwinds. Free cash flow turned negative $5.4 million versus positive $21.1 million in the prior year, raising concerns over near-term liquidity.